Pharmacology Watch – October 1, 2017
October 1, 2017
View Archives Issues
In a recent trial, when added to usual care for type 2 diabetes, investigators concluded that liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo.
Canagliflozin resulted in a lower risk of cardiovascular disease in type 2 diabetics who were at high cardiovascular risk. However, there was a higher risk of amputation, which is a new finding.
There is insufficient evidence today to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD.
In this section: The agency approves fixed-dose combination hepatitis C treatment, greenlights first U.S. gene therapy, and approves new urinary tract infection drug.